CNC
ALXN

Canandaigua National Corp’s Alexion Pharmaceuticals ALXN Stock Holding History

Canandaigua National Corp’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,463
Closed -$697K – 273
2020
Q4 		$697K Buy
4,463
+1,597
+56% +$205K 0.12% 147
2020
Q3 		$328K Buy
2,866
+637
+29% +$68.7K 0.06% 193
2020
Q2 		$250K Buy
+2,229
New +$237K 0.05% 228

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Canandaigua National Corp's ALXN Position: Q1 2021 in Review

Canandaigua National Corp sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 4,463 shares — an estimated $697K sold.

Canandaigua National Corp first reported a position in ALXN in Q2 2020 and held it in 3 quarters. The position peaked at $697K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Canandaigua National Corp reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Canandaigua National Corp sold 4,463 Alexion Pharmaceuticals shares in Q1 2021, an estimated $697K.
  • Canandaigua National Corp first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Canandaigua National Corp's Alexion Pharmaceuticals position peaked at $697K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Canandaigua National Corp's 13F filing for Q1 2021, filed 5 Apr 2021.